Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

Blayney, Douglas W.; Schwartzberg, Lee

doi:10.1016/j.ctrv.2022.102427

Cited by 30 publications

(23 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-induced neutropenia may occur in patients receiving myelosuppressive chemotherapy, and it is a potentially life-threating condition (Blayney and Schwartzberg 2022 ). Granulocyte colony stimulating factors (G-CSF)-based drugs, for example filgrastim, have been used to prevent these complications and improve prognosis (Dale et al 2018 ).…”

Section: Hematologymentioning

confidence: 99%

“…Eflapegrastim-xnst is a long-acting recombinant human hematopoietic growth factor (Cobb et al 2020 ). Eflapegrastim contains a human G-CSF analog and a half-life-extending IgG4 Fc component linked via polyethylene glycol (Blayney and Schwartzberg 2022 ). Eflapegrastim stimulates signaling pathways associated with the formation, mobilization, and function of neutrophils and decreases neutropenia.…”

Section: Hematologymentioning

confidence: 99%

See 1 more Smart Citation

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

Kaykı-Mutlu

Aksoyalp

Wojnowski

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly approved drugs in 2022 are considerably less than the 53 and 50 new drugs approved in 2020 and 2021, respectively, and less than the rolling 10-year average of 43. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify two “first-in-indication” (ganaxolon and teplizumab), 20 (54%) “first-in-class,” and 17 (46%) “next-in-class” drugs. By treatment area, rare diseases and cancer drugs were once again the most prevalent (partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics).

show abstract

Section: Hematologymentioning

confidence: 99%

Section: Hematologymentioning

confidence: 99%

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

Kaykı-Mutlu

Aksoyalp

Wojnowski

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…These emerging therapies can be grouped by their mechanisms of action: long-acting G-CSF products (efbemalenograstim alfa and eflapegrastim-xnst) and novel mechanisms (plinabulin and trilaciclib); their mechanisms of action are outlined in Fig. 1, which is taken from a review article by Blayney and Schwartzberg [9 ▪▪ ]. More detail is available in the referenced article, which also includes a helpful summary of key data and trials that led to approval of the referenced agents.…”

Section: Emerging Agentsmentioning

confidence: 99%

“…Despite numerous advances in the delivery of G-CSF, many barriers and clinical use gaps persist today, including cost, logistics of administration, and access disparities. To combat these obstacles, multiple biosimilar medications and novel agents are being introduced into the treatment landscape of CIN [9 ▪▪ ]. Novel agents include products with innovative mechanisms of action, as well as ones similar to filgrastim.…”

Section: Introductionmentioning

confidence: 99%

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

Crawford

Oswalt

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewWhile chemotherapy treatment options for patients with solid and hematologic malignancies have dramatically improved over recent years, chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) remain major barriers to delivering treatment at full doses and optimal timing. Despite concurrent advances in granulocyte colony-stimulating factor (G-CSF) administration, multiple barriers to the administration of and disparities in the access to these agents remain. The introduction of new, emerging agents, including biosimilars and novel therapies show promise in improving outcomes for CIN.Recent findingsThe introduction of biosimilar filgrastim products has improved access to G-CSF administration by driving marketplace competition and has reduced costs for both patients and healthcare systems without sacrificing efficacy. Emerging therapies to address similar issues include long-acting G-CSF products, efbemalenograstim alfa and eflapegrastin-xnst, as well as agents with novel mechanisms of action, plinabulin and trilaciclib. These agents have shown efficacy and cost-saving benefits in certain populations and disease groups.SummaryMultiple emerging agents show promise in decreasing the burden of CIN. Use of these therapies will reduce access disparities and will improve outcomes for patients with cancer receiving cytotoxic chemotherapy. Many ongoing trials are underway to evaluate the roles of these agents for more widespread use.

show abstract

“…4 The etiologic of fever in patients receiving chemotherapy in the last six weeks should be assumed is recommended. 12,13,17 Granulocyte-colony stimulating factor (G-CSF) in cancer Granulocyte-colony stimulating factor (G-CSF) is a type of growth factor that helps our bone marrow to produce granulopoiesis products called neutrophils.…”

Section: Management Of Neutropenia In Undergoing Chemotherapy Patientsmentioning

confidence: 99%

Update Management of Chemotherapy-Induced Neutropenia: A Narrative Literature Review

et al. 2023

View full text Add to dashboard Cite

One of the most frequent and significant complicated side effects of myelosuppressive drugs is neutropenia. Neutropenia is not only associated with high morbidity but also mortality. Generally, the onset of neutropenia occurs within 3-7 days after the administration of anticancer agents. Approximately 5-30% of patients will develop febrile neutropenia. The highest incidence occurs during the first cycle of chemotherapy. This literature review aimed to describe chemotherapy-induced neutropenia and its prevention and management. Administration of granulocyte colony-stimulating factor as prophylaxis can prevent neutropenia-induced anticancer drugs. The use of granulocyte colony-stimulating factor (G-CSF) as therapeutic is contradictive, and some guidelines recommend not to use the G-CSF for therapeutic purposes. Up to 70% of mortality among these populations was associated with gram-negative sepsis, therefor empirical antibiotics, and antifungals are the keys to the management of neutropenia. In conclusion, prevention and appropriate management of neutropenia are extremely important in the treatment of patients with cancer.

show abstract

Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

Cited by 30 publications

References 89 publications

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

Update Management of Chemotherapy-Induced Neutropenia: A Narrative Literature Review

Contact Info

Product

Resources

About